Tirzepatideتيرزيباتايد

Tirzepatide is the active ingredient in two FDA-approved medicines sold under different brand names for different uses: Mounjaro, used for blood sugar control in type 2 diabetes, and Zepbound, used for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is the brand name of the tirzepatide injection, registered in Jordan as an injectable (subcutaneous pen). That registration covers the injectable Mounjaro only, not any other form or brand; Zepbound's availability in Jordan has not been verified. Both are the same active ingredient, given as a once-weekly injection.

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist — it activates both of these natural hormone receptors at once, which is what distinguishes it from single-receptor GLP-1 medicines.

• It increases insulin release from the pancreas, but only when blood sugar is elevated (glucose-dependent) — it doesn't push insulin release when blood sugar is already normal or low
• It reduces glucagon, a hormone that raises blood sugar, also in a glucose-dependent way
• It slows stomach emptying, which contributes to a longer feeling of fullness
• It reduces food intake, which contributes to weight loss alongside its blood-sugar effects

• As Mounjaro (injectable, registered in Jordan): an adjunct to diet and exercise to improve blood sugar control in adults and pediatric patients aged 10 and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events
• As of December 2025, Mounjaro is also FDA-approved for children and adolescents aged 10 and older with type 2 diabetes, at a lower maximum dose — see Special Populations below
• As Zepbound (a separate brand, Jordan availability not verified here): chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity; and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity

Tirzepatide is not indicated for and has not been studied in type 1 diabetes.

Mounjaro is given as a once-weekly subcutaneous injection in adults.

Starting dose

• 2.5 mg once weekly for 4 weeks — this starting dose is for treatment initiation, not for blood-sugar effect

After 4 weeks

• Increased to 5 mg once weekly

Further titration, if needed

• The dose may be raised in 2.5 mg increments after at least 4 weeks on the current dose

Maximum dose

• 15 mg once weekly (adults)

This is educational background, not an individual prescription — your own doctor sets your exact dose and titration schedule. A lower maximum dose applies to children aged 10–17 — see Special Populations.

• Injected once a week, at any time of day
• Can be taken with or without food
• Injected under the skin (subcutaneously) in the abdomen, thigh, or upper arm
• Change the injection site with every dose
• The injection day can be moved if needed, as long as at least 3 days (72 hours) pass between doses

If you miss a dose, inject it as soon as you remember, as long as it's within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose entirely and take your next dose on your regular schedule. Never inject two doses within 3 days of each other.

• Refrigerate at 2–8°C
• Do not freeze
• Keep in the original carton to protect from light
• If needed, a single pen or vial may be kept at room temperature (up to 30°C) for up to 21 days
• Once a pen or vial has been kept at room temperature, do not put it back in the refrigerator

• Nausea and vomiting
• Diarrhea or constipation
• Decreased appetite
• Indigestion (dyspepsia)
• Abdominal pain

Not everyone experiences these, and they're often most noticeable during dose increases.

Seek medical attention immediately for signs of a serious allergic reaction: swelling of the face, throat, or around the mouth or eyes; hives; rash; itching; or difficulty swallowing or breathing.

Tirzepatide slows stomach emptying and has not been studied in people with severe gastrointestinal disease, including gastroparesis — it's generally best avoided in that situation, and tell your doctor about any known severe digestive condition before starting.

Acute gallbladder disease (including gallstones) has also been reported. Seek medical attention for severe or persistent abdominal pain, especially in the upper right area, with or without fever, nausea, or yellowing of the skin or eyes.

Acute kidney injury has been reported, most often in people who became dehydrated from nausea, vomiting, or diarrhea. Drink enough fluids, especially during dose increases, and seek medical attention for little or no urination, or other signs of dehydration alongside digestive symptoms.

Tirzepatide carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies — it is not known whether this risk applies to humans. Seek medical attention immediately if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or difficulty breathing.

A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, is a contraindication — see Contraindications.

Tirzepatide has been linked to pancreatitis (inflammation of the pancreas). Seek medical attention if you develop severe, persistent abdominal pain — which may spread to the back — with or without vomiting.

Tirzepatide hasn't been studied in people with advanced diabetic retinopathy requiring urgent treatment, or diabetic macular edema. Rapid improvement in blood sugar control can also temporarily worsen existing diabetic retinopathy. Tell your doctor about any history of diabetic eye disease, and report any changes in your vision.

• Known hypersensitivity to tirzepatide or any component of the injection
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2

Tirzepatide is not indicated for type 1 diabetes (it has not been studied in this condition), which is a separate matter from the contraindications above.

• Insulin or sulfonylureas (other diabetes medicines that can themselves cause low blood sugar) — combining them with tirzepatide increases the risk of hypoglycemia; a dose adjustment of the other medicine may be needed. Signs of low blood sugar include dizziness, sweating, hunger, shakiness, weakness, and a fast heart rate
• Oral medications in general — tirzepatide slows stomach emptying, which can affect how quickly or completely other oral drugs are absorbed; this matters most for drugs with a narrow safety margin (such as warfarin) or that depend on reaching a specific concentration quickly
• Hormonal contraceptives taken by mouth — tirzepatide may reduce their effectiveness; a backup contraceptive method is recommended for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase
• Lonapegsomatropin (a long-acting growth hormone medicine) — can reduce insulin sensitivity and may require adjusting diabetes medication doses
• Other GLP-1 receptor agonists or GIP-based medicines — combining tirzepatide with another tirzepatide-containing product or any other GLP-1 receptor agonist is not recommended (duplicate therapy)

Always tell your doctor and pharmacist about every other medicine you take.

As of December 2025, Mounjaro is FDA-approved for children and adolescents aged 10 years and older with type 2 diabetes, as an adjunct to diet and exercise. The maximum recommended dose in this age group is 10 mg once weekly, lower than the 15 mg adult maximum. This pediatric approval applies specifically to Mounjaro/type 2 diabetes — tirzepatide (as Zepbound) is not approved for weight management or obstructive sleep apnea in anyone under 18.

Pregnancy: available human data are insufficient to know whether tirzepatide affects pregnancy outcomes; animal studies suggest a possible risk to the fetus. If you become pregnant while taking tirzepatide, tell your doctor — treatment is generally discontinued once pregnancy is recognized.

Breastfeeding: a clinical study found tirzepatide undetectable or at low levels in breast milk after a single dose. There are no data yet on effects on a breastfed infant or on milk supply. This is a decision to make with your doctor, weighing the benefits of breastfeeding against your own clinical need for the medicine.

Tirzepatide may also reduce the effectiveness of oral hormonal contraceptives — see Interactions.

• Kidney disease — use with caution; see the acute kidney injury warning above
• Liver disease — use with caution
• A history of pancreatitis — discuss with your doctor before starting

See Serious Warnings above for thyroid, pancreatic, gastrointestinal/gallbladder, renal, allergic, and eye-related warning signs that need prompt medical attention.